Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.

Tiago TorresPaulo VarelaPedro Mendes BastosSofia MaginaMartinha HenriquePaulo Ferreira

Published in: Drugs in context (2024)

This study demonstrates that tildrakizumab is an effective and safe agent for the treatment of moderate-to-severe psoriasis in a diverse, real-world setting.

Keyphrases

early onset
randomized controlled trial
clinical trial
combination therapy
drug induced
atopic dermatitis